Aktis Oncology, Inc. (AKTS) return on equity (ROE)
Aktis Oncology, Inc. (AKTS) earned a return on equity of -37.6% in fiscal 2021 (the year ended June 30, 2021). That is 49.5 percentage points higher than the -87.1% of fiscal 2020. Figures as of 17 Nov 2026, 23:27 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Return on equity, fiscal 2021
- -37.6%
- Change on fiscal 2020
- +49.5 pts
- Highest on record
- -29.2%fiscal 2015
- Lowest on record
- -292.8%fiscal 2014
- Fiscal years on record
- 92014–2021
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Aktis Oncology, Inc. return on equity (ROE), in more detail
Across the 9 fiscal years on record (2014–2021), the highest was -29.2% in fiscal 2015 and the lowest -292.8% in fiscal 2014. The fiscal 2021 figure is higher than in 88% of the 8 earlier fiscal years on record, whose median is -133.4%.
Return on equity by fiscal year
Aktis Oncology, Inc. return on equity (ROE), year by year
| Fiscal year | Return on equity | Change | Year ended |
|---|---|---|---|
| 2021 | -37.6% | 49.5 pts up | |
| 2020 | -87.1% | 25.6 pts up | |
| 2019 | -112.7% | 44.3 pts up | |
| 2018 | -157.0% | 91.5 pts down | |
| 2017 | -65.5% | 136.5 pts up | |
| 2016 | -202.0% | — | |
| 2016 | -154.2% | 125.0 pts down | |
| 2015 | -29.2% | 263.6 pts up | |
| 2014 | -292.8% | — |
Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
How to read it
It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.
Aktis Oncology, Inc., figure by figure
- Aktis Oncology, Inc. market cap
- Aktis Oncology, Inc. revenue
- Aktis Oncology, Inc. earnings
- Aktis Oncology, Inc. earnings per share (EPS)
- Aktis Oncology, Inc. P/E ratio
- Aktis Oncology, Inc. P/S ratio
- Aktis Oncology, Inc. P/B ratio
- Aktis Oncology, Inc. free cash flow
- Aktis Oncology, Inc. operating margin
- Aktis Oncology, Inc. dividend
- Aktis Oncology, Inc. shares outstanding
- Aktis Oncology, Inc. total debt
- Aktis Oncology, Inc. cash on hand
- Aktis Oncology, Inc. total assets
- Aktis Oncology, Inc. return on invested capital (ROIC)
Aktis Oncology, Inc. (AKTS) overview: price, valuation and scorecard
Aktis Oncology, Inc. return on equity (ROE): questions and answers
What is Aktis Oncology, Inc.'s return on equity?
Aktis Oncology, Inc. (AKTS) earned a return on equity of -37.6% in fiscal 2021 (the year ended June 30, 2021). That is 49.5 percentage points higher than the -87.1% of fiscal 2020.
Is Aktis Oncology, Inc.'s return on equity high or low compared with its own history?
The fiscal 2021 figure is higher than in 88% of the 8 earlier fiscal years on record, whose median is -133.4%.
What are the highest and lowest return on equity figures on record for Aktis Oncology, Inc.?
Across the 9 fiscal years on record (2014–2021), the highest was -29.2% in fiscal 2015 and the lowest -292.8% in fiscal 2014.
How is Aktis Oncology, Inc.'s return on equity calculated?
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: return on equity (ROE)
All stocks guides →- Return on invested capital (ROIC) vs ROE and ROA
Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Aktis Oncology, Inc. (AKTS) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/AKTS/roe
Underlying data: the company's filings with the SEC and Yahoo Finance.